November 26th 2024
Operating in an aging facility and/or utilizing outdated equipment may lead to drug shortages and high operating costs.
Safeguarding Biologics— Blending Engineering Ingenuity and Managerial Excellence
January 1st 2023Efforts to optimize the ideal blend of technology and best practices that are needed to protect and deliver time- and temperature-sensitive biologic therapies, vaccines, and cell and gene therapies continue to evolve.
Reaction Biology Acquires Bioassay GmbH for Increasing Large Molecule Capabilities
December 5th 2022In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.